Industry
152d agoEli Lilly Invests $2.75B in Insilico
Eli Lilly's $2.75 billion investment in Hong Kong‑listed Insilico Medicine signals a global shift toward AI‑driven drug discovery, promising faster, cheaper therapies worldwide. The partnership leverages Insilico’s deep‑learning platform to accelerate target identification, potentially reducing development time by years.
The Signal
Major pharma now prioritizes AI, reshaping the industry landscape across sectors and regulatory frameworks.